Cargando…

Novel Therapeutic Strategies for Celiac Disease

Celiac disease (CeD) is a widespread autoimmune enteropathy caused by dietary gluten peptides in genetically susceptible individuals, which includes a range of intestinal and extraintestinal manifestations. Currently, there is no effective treatment for CeD other than strict adherence to a gluten-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Asri, Nastaran, Rostami-Nejad, Mohammad, Rezaei-Tavirani, Mostafa, Razzaghi, Mohammadreza, Asadzadeh-Aghdaei, Hamid, Zali, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Association of Gastroerterology and Hepatology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859609/
https://www.ncbi.nlm.nih.gov/pubmed/33564379
http://dx.doi.org/10.34172/mejdd.2020.187
_version_ 1783646770982551552
author Asri, Nastaran
Rostami-Nejad, Mohammad
Rezaei-Tavirani, Mostafa
Razzaghi, Mohammadreza
Asadzadeh-Aghdaei, Hamid
Zali, Mohammad Reza
author_facet Asri, Nastaran
Rostami-Nejad, Mohammad
Rezaei-Tavirani, Mostafa
Razzaghi, Mohammadreza
Asadzadeh-Aghdaei, Hamid
Zali, Mohammad Reza
author_sort Asri, Nastaran
collection PubMed
description Celiac disease (CeD) is a widespread autoimmune enteropathy caused by dietary gluten peptides in genetically susceptible individuals, which includes a range of intestinal and extraintestinal manifestations. Currently, there is no effective treatment for CeD other than strict adherence to a gluten-free diet (GFD). However, persistent or frequent symptoms and also partial villus atrophy were observed in some patients with CeD due to intentional or inadvertent gluten exposure during the use of GFD. It means that GFD alone is not enough to control CeD symptoms and long-term complications. Accordingly, new therapeutic approaches for CeD treatment such as gluten proteolysis, removing gluten from the digestive tract, promoting tight junction assembly, inhibiting intestinal tissue transglutaminase 2, using probiotics, and developing immunotherapeutic methods have been proposed through different strategies. This review focused on discussing the novel therapeutic strategies for CeD management.
format Online
Article
Text
id pubmed-7859609
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Iranian Association of Gastroerterology and Hepatology
record_format MEDLINE/PubMed
spelling pubmed-78596092021-02-08 Novel Therapeutic Strategies for Celiac Disease Asri, Nastaran Rostami-Nejad, Mohammad Rezaei-Tavirani, Mostafa Razzaghi, Mohammadreza Asadzadeh-Aghdaei, Hamid Zali, Mohammad Reza Middle East J Dig Dis Review Article Celiac disease (CeD) is a widespread autoimmune enteropathy caused by dietary gluten peptides in genetically susceptible individuals, which includes a range of intestinal and extraintestinal manifestations. Currently, there is no effective treatment for CeD other than strict adherence to a gluten-free diet (GFD). However, persistent or frequent symptoms and also partial villus atrophy were observed in some patients with CeD due to intentional or inadvertent gluten exposure during the use of GFD. It means that GFD alone is not enough to control CeD symptoms and long-term complications. Accordingly, new therapeutic approaches for CeD treatment such as gluten proteolysis, removing gluten from the digestive tract, promoting tight junction assembly, inhibiting intestinal tissue transglutaminase 2, using probiotics, and developing immunotherapeutic methods have been proposed through different strategies. This review focused on discussing the novel therapeutic strategies for CeD management. Iranian Association of Gastroerterology and Hepatology 2020-10 /pmc/articles/PMC7859609/ /pubmed/33564379 http://dx.doi.org/10.34172/mejdd.2020.187 Text en © 2020 Middle East Journal of Digestive Diseases This work is published by Middle East Journal of Digestive Diseaes as an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Review Article
Asri, Nastaran
Rostami-Nejad, Mohammad
Rezaei-Tavirani, Mostafa
Razzaghi, Mohammadreza
Asadzadeh-Aghdaei, Hamid
Zali, Mohammad Reza
Novel Therapeutic Strategies for Celiac Disease
title Novel Therapeutic Strategies for Celiac Disease
title_full Novel Therapeutic Strategies for Celiac Disease
title_fullStr Novel Therapeutic Strategies for Celiac Disease
title_full_unstemmed Novel Therapeutic Strategies for Celiac Disease
title_short Novel Therapeutic Strategies for Celiac Disease
title_sort novel therapeutic strategies for celiac disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859609/
https://www.ncbi.nlm.nih.gov/pubmed/33564379
http://dx.doi.org/10.34172/mejdd.2020.187
work_keys_str_mv AT asrinastaran noveltherapeuticstrategiesforceliacdisease
AT rostaminejadmohammad noveltherapeuticstrategiesforceliacdisease
AT rezaeitaviranimostafa noveltherapeuticstrategiesforceliacdisease
AT razzaghimohammadreza noveltherapeuticstrategiesforceliacdisease
AT asadzadehaghdaeihamid noveltherapeuticstrategiesforceliacdisease
AT zalimohammadreza noveltherapeuticstrategiesforceliacdisease